ScreenCell was set-up with the belief that just enumerating Circulating Tumor Cells (CTCs) without easily characterizing them was not enough to allow the early detection of a disease and to potentially follow-up the cancer progression. So it designed and produced a simple but revolutionary technology allowing the fast and effective isolation of CTCs for a better cellular and molecular characterization, which is essential in cancer monitoring. This technology also contributes to the development of a new non-invasive approach to prenatal diagnosis. Screencell is dedicated to create technologies allowing CTC to become potential end points in future oncology therapeutic arsenals, by filtering out healthy live tumor cells, thus enabling: • Molecular biology • Cell culture • Enumeration and cytomorphology evaluation For that matter, ScreenCell has designed a full range of devices (marked CE) compatible with existing In vitro Diagnostics (IVD) assays and platforms, with no need for any interface development. Our technology is now used in research studies, clinical trials, clinics and hospitals. We truly believe that our technology can make a difference in cancer diagnostics by enabling clinicians to predict the possible metastases and to monitor the cancer therapy in real time.